



*For Immediate Release*

## **LMA ANNOUNCES KEY MANAGEMENT AND BOARD CHANGES**

*Singapore, 27 November 2006* - LMA International NV ("LMA" or the "Group"), a global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, announced key management appointments and board changes as part of its ongoing management build-up and restructuring initiatives.

### *New Appointments*

#### **Chief Executive Officer, LMA**

Michael Ashton joins LMA as President and Chief Executive Officer on 1 December 2006. Michael has held increasingly senior management roles in pharma and health care companies for 30 years having worked in the international arena for Merck Inc and Pfizer Inc and as CEO of Faulding Inc and SkyePharma Plc. He holds a Bachelor of Pharmacy degree from the University of Sydney, Australia and an MBA from Rutgers University, USA.

As Chief Executive Officer, Michael will be responsible for leading the Group and accelerating the growth of its businesses and for continuing to generate sustainable shareholder value. He will be based in Jersey, Channel Islands.

#### **President and Chief Executive Officer, LMA North America**

Steve Block, currently President and Chief Operating Officer, will assume the position of Chief Executive Officer on 1 December 2006 in succession to Steve Mendell who will be retiring at the end of 2006. Steve Mendell, who has successfully built and led the Group's North American operations for the last eight years, will take on a consulting role within the Group after his retirement.

Steve Block, who joined the company in January 2005, has been in charge of sales, marketing and operations for the last two years as its Chief Operating Officer. He has been instrumental in achieving the company's recent growth and strategic objectives.

Steve has more than 20 years of health care experience of which 15 years have been in the field of anaesthesia and in medical devices and has worked in the United States and all major international markets. Prior to joining LMA North America,

Steve was acting President and Vice-President world-wide sales and marketing of Datascope Corporation's patient monitoring division.

In his new role, Steve Block will report to Michael Ashton. Also reporting to Michael will be Paul Molloy, President International, and Mike Briant, Group Chief Financial Officer.

#### *Changes to the Board of Directors*

John Lim, currently Group President, has been appointed Executive Deputy Chairman with effect from 1 December 2006 and together with Robert Gaines-Cooper, Group Chairman, will form the Board's Executive Committee. Effective the same day, Michael Ashton will join the Board while Paul Molloy and Mike Briant will step down. Both will remain key members of the Group's senior executive management team.

Robert Gaines-Cooper, Group Chairman of LMA, said, "The appointment of Michael Ashton and the internal restructuring will provide the Group with an even stronger strategic operational leadership on a global level and add depth to our management team at a time when we are seeking to grow the company both organically and by acquisition."

He added, "We see Asia as an increasingly important market for LMA and as part of our plans to increase our focus on China and India, we will be announcing new appointments to strengthen our sales teams in this region over the coming months."

- Ends -

#### **For queries, please contact**

Sharon Seetho, Gavin Anderson & Company, Singapore, +65 9009 8495

#### **About LMA**

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.